Palivizumab (Synagis) prophylaxis for respiratory syncytial virus infection in preterm infants
Record ID 32015000330
English
Authors' objectives:
Palivizumab (PLV) (Synagis; MedImmune Inc.) is an antibody used as a prophylaxis for the respiratory syncytial virus (RSV) infection, a common infection that can be serious in young babies, particularly in premature infants.
Details
Project Status:
Completed
Year Published:
2014
URL for published report:
The report may be purchased from: http://www.hayesinc.com/hayes/crd/?crd=17396
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
United States
MeSH Terms
- Antibodies, Monoclonal, Humanized
- Immunocompromised Host
- Respiratory Syncytial Virus Infections
- Infant, Premature, Diseases
- Infant, Premature
- Respiratory Sounds
- Risk Factors
- Gestational Age
- Infant, Newborn
- Treatment Outcome
- Critical Care
- Cost-Benefit Analysis
Contact
Organisation Name:
HAYES, Inc.
Contact Address:
157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name:
saleinfo@hayesinc.com
Contact Email:
saleinfo@hayesinc.com
Copyright:
2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.